Our EGT model, by combining tumor, stroma and bone microenvironment, constitutes a platform in which to investigate various treatment strategies – include, but are not limited, to bisphosphonates, anti-RANKL and hormonal therapies – to the standard of care for metastatic prostate cancer patients that can minimize dosage and bone disease. Here, TNFSF11 is linked to metastatic prostate carcinoma.